Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations Life Science Investing
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference Life Science Investing
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications Life Science Investing
Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain Medical Device Investing
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA Life Science Investing
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. in a Transaction Valued at Over $100 Million Life Science Investing
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint Life Science Investing
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery Life Science Investing
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting Psychedelics Investing
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy Ahead of Planned BLA Submission for U.S. Accelerated Approval Life Science Investing
